Effectiveness of Sublingual Buprenorphine for Pain Control in the ICU*

Author:

Patanwala Asad E.12,Moran Benjamin3,Johnstone Charlotte4,Koelzow Heike5,Penm Jonathan16

Affiliation:

1. Faculty of Medicine and Health, School of Pharmacy, The University of Sydney, Sydney, NSW, Australia.

2. Department of Pharmacy, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

3. Department of Intensive Care/ Department of Anaesthesia and Pain Management, Gosford Hospital, Gosford, NSW, Australia.

4. Department of Anaesthesia, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

5. Department of Intensive Care, Royal Prince Alfred Hospital, Camperdown, NSW, Australia.

6. Department of Pharmacy, Prince of Wales Hospital, Randwick, NSW, Australia.

Abstract

OBJECTIVES: The objective of this study was to compare pain control and opioid consumption in critically ill patients who were treated with buprenorphine sublingual or oxycodone oral/enteral during ICU admission. DESIGN: This was a retrospective, parallel, cohort study. SETTING: General medical or surgical ICUs of a quaternary, urban hospital in Sydney, NSW, Australia. PATIENTS: Data were obtained for all patients admitted to two general medical or surgical ICU from January 2019 to January 2023. Patients were grouped as those who received buprenorphine sublingual versus oxycodone oral/enteral. INTERVENTIONS: None. MEASUREMENTS AND MAIN RESULTS: Pain control was compared between a propensity score matched cohort of patients who received buprenorphine versus oxycodone. The primary outcome was the probability of significant pain. A significant pain score was defined as greater than or equal to 4 on the 0–10 Numeric Rating Scale or greater than or equal to 6 on the Behavioral Pain Scale. The study cohort included 1,070 patients (288 buprenorphine and 782 oxycodone). After propensity score matching, there were 288 patients in each group. The mean age of the matched cohort was 64 ± 16 years, 295 (51%) were male, and 359 (62%) had a surgical admission. The median probability of significant pain was 0.16 with buprenorphine and 0.17 with oxycodone (median difference, 0.01; 95% CI, –0.02 to 0.04; p = 0.50). Median opioid consumption in oral morphine milligram equivalents (MMEs) was 65 with buprenorphine and 70 with oxycodone (median difference, –1 mg; 95% CI, –10 to 10 mg; p = 0.73). Median MME per ICU day was 22 with buprenorphine and 22 with oxycodone (median difference, 1 mg; 95% CI, –2 to 5 mg; p = 0.38). CONCLUSIONS: Buprenorphine sublingual is as effective as oxycodone oral/enteral with regard to pain control and opioid consumption in the ICU. Buprenorphine sublingual is an appropriate option for patients in the ICU who are unable to take oral/enteral medications.

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Critical Care and Intensive Care Medicine

Reference18 articles.

1. Clinical practice guidelines for the prevention and management of pain, agitation/sedation, delirium, immobility, and sleep disruption in adult patients in the ICU.;Devlin;Crit Care Med,2018

2. Pain assessment and analgesic management in patients admitted to intensive care: An Australian and New Zealand point prevalence study.;Moran;Crit Care Resusc,2022

3. Bioavailability of orally administered drugs in critically ill patients.;Forsberg;J Pharm Pract,2022

4. The effect of opioids on gastrointestinal function in the ICU.;Yan;Crit Care,2021

5. Human pharmacokinetics of intravenous, sublingual, and buccal buprenorphine.;Kuhlman;J Anal Toxicol,1996

Cited by 1 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3